Assessing the Use of Solid-Phase Cytometry for Rapid Bioburden Testing
Posted on September 10, 2025
Sophie Drinkwater, Associate Director in Microbiology, AstraZeneca
Abstract The development of new and more complex modalities brings exciting opportunities to drug development, however, there are also challenges. With increased complexity often comes increased manufacturing times, cost and sometimes short shelf life. It is important the pharmaceutical microbiology...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















